{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:06:13Z","timestamp":1792037173082,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006744","name":"American Red Cross","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Most single\u2010donor platelet (SDP) donors transition to plateletpheresis after prior red blood cell (RBC) donation. Recruitment may follow identification of a high platelet count, a marker associated with iron depletion (ID). SDP donors may have underrecognized risk for iron depletion.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>To assess the prevalence of ID, we performed ferritin testing on male plateletpheresis donors with hemoglobin levels less than 13.5 g\/dL. Multivariable logistic regression identified risk factors for low ferritin (LF; ferritin \u226426\u2009ng\/mL) and absent iron stores (AIS; ferritin &lt;12\u2009ng\/mL). To assess the impact of notifying donors of LF results, we compared donation behavior of \u201cTest\u201d subjects before and after sending an LF notification letter to that of \u201cControl\u201d subjects before and after increasing the minimum hemoglobin for male donors. An electronic survey to Test donors inquired about iron supplementation practices.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Prevalence of LF was 50% and AIS was 23%, with increase in risk associated with more frequent SDP donation, both controlling for RBC donation and in donors with no recent RBC donations. Donation frequency after intervention declined less in 1272 Test donors (19%, from 13.9 to 11.2 annualized donations) than in 878 Control donors (49%, from 12.3 to 6.3 donations). Only 20% of Test donors reported taking supplemental iron when they received the LF letter; 64% of those not taking iron initiated iron supplementation following the letter.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Donors were responsive to notification of LF and attendant messaging on iron supplementation. Ferritin testing potentially benefits donor health and a stable platelet supply.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.15729","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T08:55:42Z","timestamp":1582102542000},"page":"759-768","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prevalence, risk factors, and ferritin testing to mitigate iron depletion in male plateletpheresis donors"],"prefix":"10.1111","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-9154","authenticated-orcid":false,"given":"Bryan R.","family":"Spencer","sequence":"first","affiliation":[{"name":"American Red Cross, Scientific Affairs  Dedham Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Haynes","sequence":"additional","affiliation":[{"name":"American Red Cross, Scientific Affairs  Rockville Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"IV","given":"Edward P.","family":"Notari","sequence":"additional","affiliation":[{"name":"American Red Cross, Scientific Affairs  Rockville Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5865-6366","authenticated-orcid":false,"given":"Susan L.","family":"Stramer","sequence":"additional","affiliation":[{"name":"American Red Cross, Scientific Affairs  Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13663"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15448"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13956"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12647"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03956.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15133"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02865.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03401.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12518"},{"key":"e_1_2_8_11_1","unstructured":"Food and Drug Administration Center for Biologics Evaluation and Research. Blood Products Advisory Committee 92nd Meeting November 17. 2016 Meeting Minutes. [cited 2019 Sept 29]. Available from:https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/BloodProductsAdvisoryCommittee\/UCM582198.pdf."},{"key":"e_1_2_8_12_1","unstructured":"AABB. Association Bulletin #17\u201002: Updated strategies to limit or prevent iron deficiency in blood donors. [cited 2019 Sept 29]. Available from:http:\/\/www.aabb.org\/programs\/publications\/bulletins\/Docs\/ab17\u201002.pdf."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00979.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.17945\/kjbt.2015.26.3.282"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2016.06.004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21448"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1999.7710017.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080050005001"},{"key":"e_1_2_8_19_1","unstructured":"Food and Drug Administration. Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use 21 CFR Sect. 606 610 630 640 660 820. Final Rule. [cited 2019 Sept 3]. Available from:https:\/\/www.govinfo.gov\/content\/pkg\/FR-2015-05-22\/pdf\/2015-12228.pdf."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15513"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15407"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V50.3.441.441"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1981.03310450030018"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2006.10.006"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998409006.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39070790.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14941"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13469"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.15729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.15729","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:44:30Z","timestamp":1754916270000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.15729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/trf.15729"],"URL":"https:\/\/doi.org\/10.1111\/trf.15729","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,19]]},"assertion":[{"value":"2019-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}